International Stem Cell Corp. (ISCO) Presenting At Biotech Showcase 2014 Conference
International Stem Cell Corporation announced it will be presenting at the Biotech Showcase 2014 Conference at the Parc 55 Wyndham Union Square Hotel in San Francisco, California. The conference will be taking place Monday, January 13, 2014 to Wednesday, January 15, 2014.
Dr. Simon Craw, Executive Vice President of International Stem Cell Corporation, will be presenting a corporate overview of the company and its subsidiaries. The presentation will be made in Room Mission II - Track C on Monday, January 13, 2014 at 9:30 am PST (Pacific Time).
More conference details can be found at: www.ebdgroup.com/bts/index.php
Event registration details can be found at: www.ebdgroup.com/bts/registration/index.php
International Stem Corporation is focusing its primary efforts on treatment of Parkinson's disease. The company's disease program taps into the medical power of human parthenogenetic neural stem cells for treatment. In the words of the company, these cells are "self-renewing mulitpotent cells that are precursors for the major cells of the central nervous system". With their biological capabilities, they represent a strong next-generation opportunity for treatment of Parkinson's disease.
For more information, visit internationalstemcell.com
QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.